Mechanistic insights into corticosteroids in multiple sclerosis: War horse or chameleon?☆  by Krieger, Stephen et al.
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Objectives:  Relapse  management  is  a  crucial  component  of  multiple  sclerosis  (MS)  care.  High-dose  corti-
costeroids  (CSs)  are  used  to dampen  inﬂammation,  which  is thought  to  hasten  the  recovery  of  MS relapse.
A  diversity  of  mechanisms  drive  the  heterogeneous  clinical  response  to exogenous  CSs  in patients  with
MS.  Preclinical  research  is  beginning  to provide  important  insights  into  how  CSs  work,  both  in  terms  of
intended  and  unintended  effects.  In this  article  we  discuss  cellular,  systemic,  and  clinical  characteristics
that  might  contribute  to intended  and unintended  CS  effects when  utilizing  supraphysiological  doses  in
clinical  practice.  The  goal  of this  article  is to consider  recent  insights  about  CS  mechanisms  of action  in
the  context  of  MS.
Methods: We  reviewed  relevant  preclinical  and  clinical  studies  on  the  desirable  and  undesirable  effects
of  high-dose  corticosteroids  used  in  MS  care.
Results: Preclinical  studies  reviewed  suggest  that  corticosteroids  may  act in unpredictable  ways  in  the  con-xacerbations text  of  autoimmune  conditions.  The  precise  timing,  dosage,  duration,  cellular  exposure,  and  background
CS  milieu  likely  contribute  to their  clinical  heterogeneity.
Conclusion: It  is  difﬁcult  to predict  when  patients  will respond  favorably  to CSs,  both  in  terms  of  therapeu-
tic  response  and  tolerability  proﬁle.  There  are  speciﬁc  cellular,  systemic,  and  clinical  characteristics  that
might  merit  further  consideration  when  utilizing  CSs  in  clinical  practice,  and  these  should  be explored
 201
in  a translational  setting.
©
. Introduction
High-dose steroids have been the “war horse” therapy in the
reatment of autoimmune diseases and the standard of care for
ecades [1]. Indeed, much beneﬁt has been realized for patient
are since the introduction of steroids into clinical practice in the
940s [2]. However, preclinical ﬁndings over the last several years
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suggest a re-evaluation of the therapeutic beneﬁts and adverse
effects of steroid therapy, in particular the use of high-dose steroids
for the treatment of relapses in multiple sclerosis (MS), may  be
warranted. In some cases standard practice of care persists, despite
advances in preclinical research that might suggest alternative
approaches to optimal patient care. The relationship between MS
and various comorbid conditions, including psychiatric illnesses
with likely endocrine-immune pathophysiological underpinnings,
further encourage a re-examination of the use of high-dose steroids
for MS.  Such a critical look at steroids may  not only be beneﬁcial
for understanding when steroids may  be most effective for MS
and other autoimmune disorders, but also when other therapies
should be considered. The goal of the current article is to offer a
“fresh” perspective for clinical neurologists and clinician scientists
on the convergence of recent preclinical science and mainstream
medicine related to the use of corticosteroids (CSs) in MS  care. Our
Open access under CC BY-NC-ND license.hope is that this opinion piece will foster further preclinical and
clinical research on the use of high-dose steroids for treatment
of MS.  Synthetic CS analogs have been developed to harness the
anti-inﬂammatory properties of endogenous cortisol, and we ﬁrst
license.
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Fig. 1. Circulating corticosteroid (CS) concentrations over the normal diurnal cycle, in response to acute psychological stress, and after a single 1 g intravenous methylpred-
nisolone (IVMP) treatment (depicted over a 48-h period). Measurements from original sources converted to nmol/L for comparison. The panel on the right is a magniﬁcation
of the lower section of the graph on the left. Diurnal variations of CS concentrations were assessed in healthy volunteers by immunoassay of serum cortisol levels at various
timepoints to create a daily physiological proﬁle of cortisol (purple) [17]. A maximal CS response to stress was  measured in serum samples taken from individuals during acute
military  exercises and measured by radioimmunoassay (green) [18]. Stress-induced circulating CS concentrations do not always reach this level, and can be substantially
lower than the values represented here depending on the stressor. More moderate stressors such as a laboratory psychosocial stress challenge elicit an acute stress response
of  approximately 350 nmol/L [19]. Supraphysiological concentrations of CSs are seen following treatment with a single dose of 1 g IVMP. Plasma MP  was measured by reverse
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ioactivity compared to endogenous CSs [22]. (For interpretation of the references 
onsider how they are believed to work in MS.  We then discuss
elevant preclinical and clinical reports that reveal important
nformation regarding CS treatment in MS,  including potential
imitations of treating patients with CSs. Finally, possible lessons
rom the overlap of MS  and major depression will be explored.
.  Relapse treatment
Acute  relapses in MS  are deﬁned by newly-emerging neurologic
eﬁcits that last for longer than 24 h [3]. Characteristics of these
elapses (also referred to as “attacks” or exacerbations) include
ptic neuritis, limb weakness, numbness, or brainstem episodes,
ncluding imbalance, vertigo, diplopia, and loss of facial strength
r sensation. Relapses typically develop over a day or days, per-
ist at their symptomatic peak for days to weeks, and self-resolve
ver a period of weeks to months. Approximately 50% of relapses
eave behind residual loss of neurologic function [4], contributing
o the step-wise accrual of disability in MS.  Various chronic symp-
oms, including fatigue, depression, and cognitive difﬁculties, are
ommon in MS,  particularly in the progressive stage of the illness.
hese symptoms are less common in the context of acute relapses,
ut greater awareness has led to their recognition as acute mani-
estations of MS  in some instances.
On a pathophysiological level, acute relapses are considered to
e a clinical manifestation of new inﬂammatory activity in the
entral nervous system (CNS). Multiple sclerosis lesions generally
ccur around small venous vessels, and are thought to be driven
y autoreactive T-cells that cross the blood brain barrier (BBB) and
rchestrate an attack on myelin [5]. In many patients, the disease
rogresses to a neurodegenerative phase and the immune response
o the acute injury progresses to a more chronic inﬂammatory state
hat includes activated immune responses from local immune cells,
-cells, B-cells, macrophages, and microglia [5–8]. As our under-
tanding of the speciﬁc immunopathology that contributes to MS
esions has expanded, so has our appreciation for active inﬂam-
atory lesions being associated with axonal transection and loss
9]. Incomplete recovery from early relapses is common [10] and
as been associated with a worse prognosis [11]. This suggestseven higher circulating concentrations of MP [21], and MP  is known to exert greater
r in this ﬁgure legend, the reader is referred to the web  version of this article.)
that  neuronal vulnerability after a relapse has important clinical
implications.
The clinical management of MS  includes interventions that are
intended to: (1) prevent relapses and the accumulation of disabil-
ity; (2) hasten resolution of acute relapses (i.e., “abortive” therapy);
and (3) manage MS-related symptoms. Preclinical and clinical
research of MS  therapies has focused primarily on the ﬁrst of these
through the development of disease-modifying therapies (DMTs).
While DMTs are the standard of care in MS  for chronic treatment to
prevent relapses, none do so completely [12], making the prompt
recognition and treatment of relapse a primary challenge in MS
therapy. Abortive treatment of acute relapses is used to bring about
a faster resolution of relapse symptoms than would be expected to
occur naturally.
Corticosteroids, which include the stress hormone cortisol, have
robust anti-inﬂammatory properties and have been a mainstay of
treatment in MS  ever since the discovery in the 1940s that their
therapeutic effect in the context of autoimmune conditions was
beneﬁcial. High-dose CSs are currently the mainstay treatment for
acute MS  relapses [13–15]. The current standard treatment for
acute relapses in MS  is a supraphysiological dose of intravenous
(IV) methylprednisolone (MP) 1 g/day for 3–5 days, which was
derived from the Optic Neuritis Treatment Trial [16]. This dose
of MP  is much greater than the amount of endogenous CS pro-
duced during normal circadian cycles or in response to stress (Fig. 1)
[17–22]. A few key studies have examined the tolerability and efﬁ-
cacy of high-dose steroids versus placebo in MS  relapse (Table 1;
Durelli [23], Milligan [24], Beck [16], Barnes [25], Sellebjerg [26];
for more detailed reviews of relapse treatments and high-dose
steroids, see Berkovich 2012 [27], Filipini [28], Miller [29], Burton
[30]). Less widely employed treatments for MS relapses include
plasmapheresis, IVIg, and Acthar Gel. These treatments are well
beyond the scope of the current discussion, and are reviewed else-
where [12,31].It  is widely known that CS treatments can lead to both desir-
able and undesirable effects depending on the type of steroid
and the situation in which it is used. Although CSs are frequently
effective for shortening relapses in MS,  they also often exhibit
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Table  1
Key  studies of high-dose corticosteroids in the treatment of multiple sclerosis exacerbation.
Reference Patient allocation (n) Efﬁcacy Side effects (n)
Durelli et al. (1986) [23] IVMP high dose
(13  + 10 cross-over
from placebo)
At  day 1–3, 13 reported subjective
improvement
At  day 3–6, 12 reported clinical
improvement  + additional improvement in
9 crossed from placebo group
Unusual taste in mouth after infusion (5)
Elevated mood and insomnia (12)
Slight weight gain and edema (10)
Placebo  (10) At day 4–8, 6 reported subjective
improvement
By  day 11, clinical improvement was
reported in 4
None  reported
Milligan et al. (1987) [24] IVMP high dose (13) At week 4, 10 had decrease in disability
score
No serious adverse events; reports of ﬂushing, transient
ankle  swelling and metallic taste in the mouth during
infusion
Placebo (9) At week 4, 2 had decrease in disability
score
None reported
Beck et al. (1992).a [16] IVMP high dose (144) At day 30, 112 did not have normal visual
acuity
At 6–24 months, 20 were diagnosed with
MS
Serious adverse events: acute transient depression
requiring medication (1); acute pancreatitis (1)
Minor side effects (not quantiﬁed): sleep disturbances,
mild mood change, stomach upset, facial ﬂushing,
weight gain
Oral prednisone low
dose  (151)
At  day 30, 123 did not have normal visual
acuity
At 6–24 months, 35 were diagnosed with
MS
Minor side effects (not quantiﬁed): sleep disturbances,
mild mood change, stomach upset, facial ﬂushing,
weight gain
Placebo (143) At day 30, 125 did not have normal visual
acuity
At 6–24 months, 28 were diagnosed with
MS
None reported
Barnes et al. (1997) [25] IVMP high dose (38) At week 4, median change of 0.5 on EDSS No serious side effects; adverse events not reported
Oral MP  low dose (42) At week 4, median change of 0.5 on EDSS No serious side effects; adverse events not reported
Sellebjerg et al. (1998) [26] Oral MP  high dose (26) At week 8, 17 deﬁned as responders Insomnia (17), gastrointestinal symptoms (10), hot
ﬂashes  (7), palpitations (7), dysphoria (6), edema (5),
musculoskeletal pain (4), acne (3), weight gain (3),
headache (2), metallic taste (2)
Placebo  (25) At week 8, 8 deﬁned as responders Insomnia (2), gastrointestinal symptoms (2), palpitations
(1), dysphoria (1), edema (2), musculoskeletal pain (1),
headache  (1), metallic taste (1)
Expanded Disability Status Scale (EDSS), IV, intravenous; MP,  methylprednisolone.
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igh-dose steroids, although the patients in this study had solely optic neuritis and
ide effects that require active management [32,33]. Gastroin-
estinal side effects include abdominal discomfort, gastritis and
eptic ulcer, and unpleasant metallic taste. Changes in mood and
nergy levels range from mild insomnia to euphoria to frank psy-
hosis. Sodium and water retention leading to weight gain and
eripheral edema are common transient side effects, as is con-
omitant potassium wasting and hypokalemia. Other important
ut transient metabolic effects include elevated blood glucose lev-
ls, and systemic side effects such as elevated blood pressure
nd acne. Cardiac arrhythmias and conduction disturbances have
een reported in MS  patients treated with high-dose IVMP [34]. In
atients with underlying medical comorbidities that may  amplify
he adverse event proﬁle, high-dose steroids must be used with
aution; these comorbidities include diabetes, mood disorders such
s major depression, a history of psychosis, and cardiac arrhythmias
r bradycardia [15]. In such cases, in-patient monitoring during
teroid dosing may  be warranted. Steroids should be used carefully
n patients with a history of glaucoma or osteoporosis, or in a set-
ing of recent or recurrent infection. In order to understand these
ndesirable outcomes during CS therapy, it is important to consider
hat synthetic CSs may  exert their effects via mechanisms different
rom those involved with endogenous cortisol.
Although there is a general consensus that CSs are effective in
he context of MS  relapses, there is a relative absence of information
bout whether or not CS treatment brings about a more complete
esolution of symptoms than would ultimately occur without treat-
ent. Furthermore, our recent review of the literature did not
ncover evidence indicating that not treating a relapse would leadcause it had a signiﬁcant impact on current standard of care regarding the use of
ther MS relapses.
to  more frequent or severe subsequent relapses. Given this uncer-
tainty, and the side effect proﬁle and potential toxicities of CSs, it is
not standard practice to treat all relapses. However, relapses that
are disabling or cause functional impairment are generally treated
[12]. Mild relapses, such as an area of tingling or paresthesias in
the absence of signiﬁcant sensory loss, may  be simply allowed to
recover without CS treatment.
Another application of CSs that is particularly relevant to this
discussion is the use of monthly high-dose steroids for 1–3 days.
This is sometimes referred to as “pulse dosing” and is utilized in
response to uncontrolled disease that may  not qualify for the clin-
ical deﬁnition of relapse. One study that examined the effects of
repeated high-dose IVMP over a 5-year period showed that the
treatment resulted in less brain atrophy than placebo [35]. A sub-
sequent study, however, found that IVMP resulted in a decrease in
brain volume over the subsequent 8 weeks after steroid administra-
tion [36]. Patients with secondary progressive MS  showed a greater
decline in brain volume following IVMP than relapsing-remitting
MS (RRMS) patients, suggesting pathological heterogeneity in the
development of steroid-related outcomes as the disease course pro-
gresses.
Clinical outcomes for MS  treated with repeated pulse dosing
of IVMP have similarly been variable. A small cross-over study
in RRMS showed that the addition of a single monthly dose of
500 mg  IVMP followed by a 3-day oral taper reduced the number of
gadolinium-enhancing lesions on monthly MRI  scans for 12 months
[37]. The larger NORMIMS study evaluated monthly oral dosing of
200 mg  MP  daily for 5 days versus placebo as an add-on therapy to
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nterferon beta-1a in RRMS, with yearly relapse rate as the primary
utcome [38]. The study showed that this pulse-dosing strategy
ielded a signiﬁcant reduction in relapse rate. It bears mention that
leep disturbances and other neuro-psychiatric symptoms were the
ost frequent adverse events in the methylprednisolone group. In
ontrast, the MECOMBIN study also studied the addition of pulse-
osed MP  (500 mg  orally per day for 3 days monthly) or placebo to
nterferon beta-1a, and found that the addition of monthly pulses of
P  did not prevent or delay disability progression more than inter-
eron beta-1a treatment alone [39]. These results are thus incon-
lusive and longer-term outcomes are unavailable at this time.
In  keeping with the heterogeneous nature of MS,  on an individ-
al basis there is great variability in the severity of relapses, their
xtent and timing of recovery, and the degree to which relapse
ecovery is responsive to CS therapy. Because steroid treatment is
ften not initiated as soon as relapse symptoms begin, and stud-
es have utilized a wide range of relapse durations and timing of
linical endpoints, it is difﬁcult to know precisely how fast, or how
ompletely steroids attenuate the clinical symptoms of MS  relapse.
orticosteroid treatment is often employed repeatedly in a single
atient over the course of their disease. The unpredictability of
esponse exists both within and between patients, as the clinical
esponse to CS treatment for one relapse does not necessarily pre-
ict response for the same patient in subsequent relapses. Although
 history of failing to respond to steroids cannot rule out their use
o treat a subsequent relapse, failing to respond can be taken in
o account when considering the beneﬁt/side effect risk calcula-
ion. This is because the clinical response to steroid treatment often
ecreases over time [40].
The  mechanism of this therapeutic decrement is not clear. One
ossible reason for decreased effectiveness of CSs is “steroid resis-
ance.” However, steroid resistance in MS  has not been thoroughly
tudied, and some patients may  be inherently less responsive to
Ss. Alternatively, CSs may  become less effective as MS becomes
ess of an inﬂammatory-mediated disease with de novo inﬂamma-
ory attacks, and more a disease of neurodegeneration and failure
f compensatory strategies. A clearer picture of why  CSs lose efﬁ-
acy during MS  would thus improve not only our understanding of
he efﬁcacy of steroid treatments, but also our understanding of the
arious ways in which this disease may  progress. It would be helpful
o better understand the extent to which CSs provide clinical ben-
ﬁt in different phases of MS.  It would also be worthwhile to know
hether or not the suppression of inﬂammation is universally
ffective, or if it occurs at the cost of collateral CS-mediated dam-
ge in the CNS. The remainder of the article will brieﬂy review the
echanisms likely involved with the clinical “unknowns” involving
Ss in MS,  including individual variability in responsiveness, thera-
eutic decrement, steroid resistance, on-going neurodegeneration,
nd the role of comorbid conditions such as major depression in
atients with MS  who are non-responsive to CS.
.  The anti-inﬂammatory mechanisms of CSs
The best understood mechanisms of CS function are mediated
ia the genomic actions of intracellular glucocorticoid receptors
GRs). Like other nuclear hormone receptors, these receptors
emain inactive in the cytosol until they bind ligand, either the
ndogenous CS cortisol or a synthetic CS. Activated receptors
hen translocate to the nucleus where they act as transcription
actors by binding to discrete regulatory regions of DNA called the
lucocorticoid response element (GRE) to modulate the expression
f genes that affect activities ranging from immune function to
etabolism [41,42]. There are two CS-responsive intracellular
eceptors: the GR and the mineralocorticoid receptor (MR). These
eceptors differ both in their afﬁnity for different CSs as well as
heir central and peripheral distributions. Glucocorticoid receptor Neurosurgery 119 (2014) 6–16 9
is  found in almost all areas of the brain and body, while MR  is
conﬁned to the hippocampal formation and lateral septum in the
brain and the kidney [42,43]. Furthermore, the MR  has a high
binding afﬁnity for the endogenous CS, cortisol (approximately
Kd = 0.5–1.0 nM), resulting in the vast majority of MR  being toni-
cally bound by cortisol, even at basal physiological concentrations.
In contrast, GR exhibits a much lower afﬁnity for cortisol (approx-
imately Kd = 2.5–5.0 nM)  and is only activated by cortisol during
periods of moderate to severe stress or at the circadian cycle peak
[42]. Because most synthetic CSs preferentially bind the GR when
used at therapeutic doses, the majority of studies on autoimmune
disorders and intracellular receptors for CSs have focused on this
particular receptor. However, it is important to note that several
synthetic CSs do exert an effect at the MR  [44].
Genomic actions mediated via GR signaling are widely believed
to be responsible for the anti-inﬂammatory actions of CSs (Fig. 2).
For example, expression of genes coding for the anti-inﬂammatory
cytokine interleukin (IL)-10 and the protein inhibitor -B (IB)-
 increases when GR binds to a GRE upstream of either [45]. The
genomic effects of CSs are made less predictable by the fact that GR
is subject to alternative splicing, leading to receptor variants with
different functionality [46]. Homodimers of GR are the “classic”
receptor isoform; however, low-level expression of an alternative
splice form GR [47] that is also able to dimerize with GR  [48]
results in GR/ heterodimers that are less active [49]. The bal-
ance of GR isoforms has been shown to be important for illnesses
with pathophysiological processes known to involve CSs. For exam-
ple, CS resistance in leukemia has been linked to high expression
levels of GR relative to GR in cultured patient lymphocytes [50].
Additionally, increased expression of GR has been identiﬁed in
rheumatoid arthritis, a disorder that critically involves inﬂamma-
tory excess [51]. Finally, medically healthy patients with major
depression have been reported to have a lower GR to GR ratio
[52]. These data suggest that the balance of GR and GR may be
important for understanding disease states involving inﬂammatory
immune alterations. Indeed, one explanation for the decrement in
clinical response to CSs in MS,  particularly as the disease progresses
[40], may  be that resistance to CSs results from a shift in the relative
balance of GR and GR. Although preliminary studies have not
supported this hypothesis [53], more work in this area is needed.
Activated  GRs have also been shown to inﬂuence cell function
in ways not involving direct DNA binding, but instead via exten-
sive protein–protein interactions within many other molecular
signaling pathways [41] (Fig. 2). In contrast to the direct genomic
effects of CSs, these nongenomic effects of CSs, also mediated by
the GR, have been far less studied. However, it is likely that a
signiﬁcant portion of CS effects in health and disease are medi-
ated by nongenomic effects involving protein–protein interactions
between the GR and other signaling pathways, including effects
of CSs on immune function [41]. For example, activated GRs  have
been shown to bind to the transcription factor nuclear factor-B
(NF-B) in the nucleus, which in turn blocks NF-B from bind-
ing to DNA and impairs enhancement or inhibition of genes that
are normally regulated by NF-B to increase inﬂammation [54].
This nongenomic effect of GR on the NF-B pathway may  be one
of the primary mechanisms by which CSs exert anti-inﬂammatory
effects. Conversely, increased activity of a number of signaling path-
ways involved with the inﬂammatory system have been shown
to impair GR function, including p38 mitogen-activated protein
kinase (MAPK) and Janus kinase-signal transducers and activators
of transcription (JAK-STAT) [55,56]. This reveals the possibility that
excessive activation of these signaling pathways may  lead to glu-
cocorticoid resistance [57].
Corticosteroids, particularly at very high doses, may  also exert
nongenomic effects on immune function that do not involve intra-
cellular receptors such as GR (Fig. 2). Instead, preclinical studies
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Fig. 2. Corticosteroids (CSs) act on multiple intracellular signaling pathways to modify inﬂammatory gene transcription. Although they canonically work by binding to the
cytosolic  glucocorticoid nuclear hormone receptor (GR), CSs also have rapid effects through poorly understood membrane-bound receptors, and many of their downstream
effects cross-talk with other aspects of the inﬂammatory signaling cascade. Corticosteroids bind to GR, resulting in dissociation of heat shock protein (HSP, here HSP 90)
complexes and subsequent receptor phosphorylation. Glucocorticoid receptor then translocates to the nucleus where it dimerizes and either interacts with other transcription
factors or binds to glucocorticoid response elements (GREs) upstream of GR-regulated genes including those that code for proteins critical to inﬂammatory pathway function
(e.g.,  inhibitor -B [IB]). The proinﬂammatory transcription factor nuclear factor-kappa B (NF-B; shown here as the P65 and P50 Rel subunits) is normally activated
by extracellular inﬂammatory signals such as cytokines (via their receptors, here the receptors for interleukin [IL]-1 or interferon [IFN]-) or direct pathogenic cues (e.g.,
lipopolysaccharide) acting through toll-like receptors (TLRs; here TLR4). Activation of cytokine receptors and TLRs also results in the activation of other inﬂammatory
signaling pathways, including the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathways, the activator-protein-1 (AP-1) pathway, and the p38
mitogen-activated protein kinase (MAPK) pathway. Activity of inﬂammatory signaling pathways is modiﬁed by CSs at several levels. For example, GR can bind directly to
NF-B  to block activation of genes coding for proinﬂammatory cytokines with response elements (REs) for NF-B. Glucocorticoid receptor can also impact NF-kB pathway
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 (MKP1), which negatively regulates MAPK pathways including ERK. Glucocortic
nhibitory protein–protein interactions, which prevents binding of AP-1 to its RE.
uggest that the rapid therapeutic effects of CSs, including pulse
herapies (e.g., 1 g IVMP for 1–3 days administered once a month
s preventative therapy) for MS,  may  act on cells by changing
hysiochemical properties of their membranes [41]. For exam-
le, cortisol has been shown to increase membrane ﬂuidity [58].
mmune cell apoptosis induced by high-dose glucocorticoids may
nvolve effects of CSs on mitochondrial membrane permeability
59]. In rat thymocytes, several synthetic CSs commonly used in
S relapse treatment have been shown to lead to differential
hanges in intracellular calcium concentrations, despite having
imilar genomic receptor afﬁnities [60]. Corticosteroids may  also
xert their effects through membrane-bound CS receptors (Fig. 2),
ncluding a variant of GR that resides within the cell membrane. The
embrane GR has been associated with caveloae contained in the
ell membrane, which also are associated with G-protein coupled
eceptor signaling [58].
The  speciﬁc concentration of CSs that a particular cell receives
s also critical in determining CS actions. Unfortunately, several
actors make it difﬁcult to determine the actual dose of CSs that is
felt” at a cellular level from a given delivery regimen. First, CSs are
ubject to multiple levels of regulation (e.g., differential bindinge coding for IB. Also shown here is GR-mediated expression of MAPK phosphatase
ceptor also interacts with the AP-1 (comprised of Fos and Jun subunits) through
to  carrier proteins in the blood and local inactivation by degrading
enzymes) from the time they are released into the blood until when
they enter target cells, so concentrations of CSs in blood do not nec-
essarily predict GR signaling within a single cell of a complex tissue
[61]. A better understanding of the local tissue concentrations of
CSs resulting from different administration regimens is therefore
required. Second, GR signaling is likely to carry different conse-
quences depending on the cell type in which it occurs, based on the
widespread GR expression throughout many CNS cell types, and
variability in GR isoforms. Third, CS concentrations are sensitive to
multiple factors, including the timing and duration of CS exposure
relative to circadian peaks and troughs in endogenous CS produc-
tion, whether the CSs are synthetic and substrates for multi-drug
resistant transporters or endogenously released from the adrenal
glands post-injury, and the speciﬁc tissue in which CSs are acting.
Finally, CSs affect not only the genes that they directly activate, but
also may  have concentration-dependent effects on other transcrip-
tion factors and the genes they regulate (i.e., nongenomic effects).
When using synthetic CSs in therapeutic settings, supraphysiolog-
ical dosing strategies are typically employed, which may  eliminate
concerns about differential dosing through a ceiling effect, but
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ifferences in the timing of their administration may  still be
ritical.
Both genomic and nongenomic CS effects are likely relevant in
he context of MS,  as the full constellation of CS actions are likely
o determine the clinical response. Given our currently limited
nderstanding of how intracellular GRs bind to proteins associated
ith other signaling pathways, as well as the possible effects of
Ss mediated by membrane-bound receptors, the role of nonge-
omic effects of CSs are much harder to elucidate in the context
f MS  pathophysiology. However, these nongenomic effects and
he actions of CSs directly on cell membranes may  explain some of
he unexpected outcomes seen with CS therapy. It is quite pos-
ible that the effects of high-dose glucocorticoids are mediated
hrough nongenomic mechanisms that do not involve GR [60]. More
esearch is required to understand the relative importance of these
ifferent mechanisms of CSs in MS,  where CS treatment is a main-
tay therapy.
.  Revising our understanding of CSs
The more than half-century old view that CSs universally sup-
ress immune responses has been updated in the past decade,
eginning in part with studies on various aspects of the biolog-
cal response to stress. Work from several laboratories strongly
uggests that at the beginning of the stress–response, CSs have
ermissive, immunostimulatory effects [62]. The early immunos-
imulatory effect of stress is partly due to the short-lived activation
f the sympathetic nervous system [63]. However, acute expo-
ure to CSs can also increase the early activation of the immune
esponse to injury [64]. In the later phases of the injury, increasing
oncentrations of CS secreted in response to stress constrain and
acilitate recovery of the immune response exerting the classically
escribed immunosuppressive effect. These ﬁndings have impor-
ant implications for how we understand and use CSs in the context
f MS.
Importantly, this updated view that includes CS-activated
mmune responses does not challenge the traditional view that
tress levels of endogenous CSs and pharmacological levels of
ynthetic CSs are immunosuppressive. However, contemporary
nvestigations have identiﬁed situations where even high-dose,
hronic CS treatments failed to suppress, and in some cases
ncreased, immune responses to CNS inﬂammation [65]. The com-
on  ﬁnding from these studies was that even sustained occupancy
f GR can have proinﬂammatory effects on CNS inﬂammation, pre-
ominantly when CS exposure occurs prior to injury [66–72]. These
tudies indicate that for the MS  patient, factors that may  be impor-
ant during disease treatment are: stressors, mood disorders, and
enetic variability. These three factors may  all converge to create an
ndogenously complex CS exposure pattern that is likely to impact
he individual response to therapeutic CSs.
Recent studies suggest that the most important factors
etermining whether CSs will decrease inﬂammation, increase
nﬂammation, or fail to have an effect all together include: (1) the
ype of CNS injury; (2) the timing and duration of CS exposure;
nd (3) the amount of CS delivered. Different types of inﬂamma-
ory injury are likely to have different pathophysiological processes,
ith differential steroid sensitivity (even relapse-to-relapse).
urrently available rodent models in which CSs have been tested
hat might serve as a model of some aspects of the acute inﬂamma-
ory injury that occurs during an MS  relapse are lipopolysaccharide
LPS)-induced inﬂammation, focal excitotoxic injury, and exper-
mental autoimmune encephalomyelitis (EAE). More appropriate
odent models like EAE are being studied to generate a better
nderstanding of how CSs affect processes that are more speciﬁc
o MS  [73,74]. Neurosurgery 119 (2014) 6–16 11
The timing of CS exposure is one of the most important param-
eters that can lead to an unexpected inﬂammatory response to
injury. Exposure to CSs prior to injury is particularly likely to lead
to future exacerbated inﬂammatory responses. In animal models, a
single exposure to stress-level CSs has been reported to stimulate
both CNS and peripheral immune responses [74–76], provided that
it occurs prior to or at the same time as the inﬂammatory challenge.
In rats, CS exposure stimulated cytokine release if it occurred 2 h
ahead of peripheral LPS challenge, but was  suppressive if CSs were
given 1 h after the challenge [75,76]. The enhanced inﬂammatory
response in the brain is relatively long-lived, being observable for
at least 4 days following the acute stressor [77]. In an EAE model,
CSs given at the time of immunization worsened disease symptoms
and was  associated with increased inﬁltration of leukocytes into the
CNS [74]. Stress levels of CSs beginning 12 h prior to immune stimu-
lation via LPS treatment in healthy human adults potentiate plasma
IL-6 and tumor necrosis factor (TNF)- [78–80]. These ﬁndings indi-
cate that prior stress can have stimulatory effects on subsequent
immune responses, an effect that has been described as CSs prim-
ing the inﬂammatory response to injury [81]. Several studies have
found that CSs given at the same time as or following an inﬂamma-
tory challenge are more likely to have classic anti-inﬂammatory
effects [82,83].
In  the context of MS,  treatment with CSs does not often pre-
cede acute inﬂammatory injury. However, treatment of relapses
with CSs may  precede (and could therefore possibly potentiate)
certain aspects of the chronic inﬂammatory state that devel-
ops with recurring injury. This hypothesis remains untested in
existing rodent models. Given the sensitivity of the relationship
between CSs and the immune response, it is possible that chronic
inﬂammation, signiﬁcant life stressors, and acute injury may  have
unexpected responses to CSs, particularly when they are given at
supraphysiological doses having both genomic and nongenomic
effects. Another scenario where this may  be of importance is when
a patient fails one round of CS therapy and is retreated with
CSs. Although these theories require more research, we  suggest
that patients with certain characteristics, such as CS resistance or
CS system response to frequent exposure to stressors, may  war-
rant some additional consideration before being retreated with
CSs.
Because of their clinical relevance, the properties of synthetic
CSs are pervasively explored in the literature, albeit with limita-
tions regarding supraphysiological dosing strategies. Care must be
taken when considering the actions of these compounds, as they
are frequently quite different than the effects of endogenous CSs.
Methylprednisolone, for example, is 5 times more potent than
cortisol at the GR [22]. A concerted effort is needed to under-
stand the differences between how endogenous and synthetic CSs
affect inﬂammation in the CNS. Much work remains to be done
to fully understand what factors dictate whether CSs exert pro-
or anti-inﬂammatory effects in the CNS. For now, we can deﬁne
several trends among the diverse CS effects on inﬂammation:
low-to-moderate doses, acute exposure, and CS presence prior to
inﬂammation all tend to augment the inﬂammation, whereas high
doses, chronic exposure, and CS presence after inﬂammation tend
to suppress it [64,65,84–86]. However, the rules about how these
parameters interact are still undetermined and there are virtually
no data available describing the CNS effects of supraphysiological
doses (e.g., 1 g IVMP). The evidence discussed thus far suggests that
in the context of stress and immune challenge, CSs play a complex
role in orchestrating an optimal and timely response that main-
tains control over the potentially damaging effects of an excessive
immune response, such as that found in patients with MS.  More
generally, these studies indicate that clinical assumptions about the
universal immunosuppressive effects of CSs should be reexamined
in the most objective ways possible.
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. Side-effects associated with compromised remyelination
nd  neuron death
Although  CSs are the standard therapy used to treat MS  exa-
erbations, several lines of evidence suggest that treatment with
Ss may  not always produce the expected clinical outcomes.
everal studies have reported mixed results with respect to the
xtent and timing of MS  relapse improvement [10,87,88]. Although
ore recent insights into the effects of CSs on inﬂammation sug-
est that CS therapies may  sometimes activate or fail to inhibit
he immunopathophysiological underpinnings of MS  in certain
ituations, other unexpected effects of CSs may  also involve non-
nﬂammatory endpoints. Indeed, CSs have been shown to have
otent direct effects on neuronal survival and remyelination, irre-
pective of their effects on immune cells.
As discussed, CSs have also been found to lead to the expression
f psychiatric abnormalities, including depression, mania, and psy-
hosis [89], suggesting that CSs have potent and rapid effects on
eurotransmitter systems that critically regulate mood and behav-
or. Taken together, these studies suggest that CSs could exert
owerful and unexpected effects in the CNS besides those related to
acrophages, microglia, and autoreactive T-cells. Corticosteroids
ay also have potent effects on spinogenesis, or the formation
f dendritic spines on neurons. Both stress-induced cortisol and
xogenous corticosterone treatment resulted in decreased spino-
enesis in the basolateral amygdala [90], while others found similar
esults of decreased spinogenesis and dendritic arborization in the
ippocampus and frontal cortex, but not in the amygdala [91,92].
orticosteroids are well known to be important for learning pro-
esses at lower physiological concentrations, and have been shown
o inhibit learning at higher concentrations [93,94].
Corticosteroid treatments have been known for decades to exac-
rbate neuron death during a wide variety of necrotic neurologic
njuries, including hypoxia–ischemia [95] and excitotoxicity [96].
urthermore, CS effects on immune cells may  actually contribute
o this worsened neuron death [97]. One important preclinical
tudy suggests that CSs may  also increase neuron death in MS
98]. This study investigated the effects of short-course, high-dose
P treatment on retinal ganglion cells in the rat model of EAE.
hile imperfect, the generation of myelin-reactive T-cells in EAE
s nonetheless an instructive animal model of MS,  and the short, but
igh-dose paradigm used in that study is analogous to current clini-
al practice. This study quantiﬁed optic neuritis by recording visual
voked potentials, or the change in electrical activity within reti-
al ganglion cells, from before to immediately after presentation
f a light stimulus. The high-dose MP  treatment did not improve
isual function in EAE animals as measured by evoked potentials,
nd instead promoted increased apoptosis of retinal ganglion cells,
he neurons that form axons of the optic nerve. This deleteri-
us effect of MP  on cell survival was found to be nongenomic,
ot dependent on the GR, and dependent on MAPK pathways.
his work suggests that for some neurons, or in certain brain
egions, high-dose CSs can be neurotoxic in the context of MS  dis-
ase activity independent of GR-mediated effects on inﬂammatory
ctivity.
In addition to effects on neurons, CSs also impact oligodendro-
ytes and interfere with remyelination and repair processes after
amage by autoreactive T-cells. Recovery after MS  exacerbations
equires remyelination, as oligodendrocytes attempt to “replace”
yelin destroyed by autoreactive T-cells. This type of formation
as been described as shadow plaques [5]. Recently, Clarner and
olleagues used the non-immune cuprizone model of MS  to explore
he impact of 9 or 21 days of high-dose MP  on various markers of
yelination in the corpus callosum [99]. Although previous studies
ave explored the effects of CSs on remyelination in the spinal cord
ith conﬂicting results [100–102], Clarner and colleagues are the Neurosurgery 119 (2014) 6–16
ﬁrst  to do so systematically in the brain. As expected, cuprizone
treatment resulted in decreased expression of the oligodendro-
cyte differentiation marker, proteolipid protein (PLP), in the corpus
callosum. Methylprednisolone treatment for 9 days after cuprizone
was found to further reduce the expression of PLP compared to
cuprizone alone. This effect remained when animals were treated
with MP  for 21 days instead of just 9 days and suggests that CS treat-
ments, especially at high doses such as those given to MS patients,
can potentially impede remyelination. Given the ethical constraints
of conducting equivalent studies in humans, and despite requir-
ing careful interpretation with the proper caveats, these preclinical
models are of considerable importance for understanding how CSs
may  act in MS  patients.
6.  Autoimmunity, major depression, and CSs
Multiple sclerosis and major depression are highly comorbid
conditions, suggesting a possible link between the two that may
critically involve resistance to CSs [103]. Depression is one of the
many clinical aspects of MS  that might warrant special attention;
it is an example of how preclinical data can provide insight into the
interplay between mood, immunology, and the CNS that is a critical
part of the clinical puzzle. Often unrecognized and untreated, major
depression represents a signiﬁcant threat to long-term quality of
life for patients with MS.  Untreated depression may also threaten
compliance, with adverse effects on overall treatment outcome.
Patients with MS  have been found to have a lifetime risk of depres-
sion of 25–50% [104,105], and a recent large community-based
study  found that 40% of patients with MS  have clinical depres-
sion symptoms [106]. Although it was  originally thought that DMTs
such as interferon (IFN)-1b could be depressogenic [107], a lon-
gitudinal study suggests this may  not be the case [108]. Instead,
prior depression may  be most predictive of the development of
major depression after starting DMTs [109,110]. Aspects of the dis-
ease that may  contribute to this higher rate of major depression
among MS  patients include three primary factors: (1) direct effects
of damage from the disease; (2) the psychological effects of the
unpredictable nature of the disease; and (3) the chronic inﬂamma-
tion associated with MS.
Multiple  sclerosis lesions often occur in brain regions that are
essential for healthy mood regulation and are altered in major
depression, including the prefrontal cortex, the hippocampus, and
the amygdala. Indeed, brain morphometric or functional changes
in MS  patients that are associated with major depression have
been assessed using diffusion tensor imaging, quantitative mag-
netic resonance imaging (MRI), and atrophy measured by MRI
[104,111,112]. Secondly, the chronic psychological stress aspect of
MS  may  also play an important role in the high rate of depression
in these patients. Patients with MS  are often confronted with the
unpredictable nature of the illness, which may  encourage feelings
of loss of control, or a “learned helplessness” state [113]. Thirdly,
research into the relationship between major depression and the
immune system suggests that imbalances in immune function in
MS may  contribute to the development of major depression in
patients. Although major depression is widely believed to involve
imbalances in brain neurotransmitter systems [114], as well as
over- or under-activation of discrete brain areas that are respon-
sive to traditional antidepressant treatments [115], ongoing work
on the pathophysiology of depression suggests that a signiﬁcant
portion of depression cases also involve alterations in immune
function [116,117]. This opens up the possibility that for some
MS patients also suffering from depression, a somewhat common
underlying pathophysiological mechanism of immune dysregula-
tion may  exist for both conditions.
Major depression has also been associated with CS resis-
tance in medically healthy patients, as evidenced by abnormal
S. Krieger et al. / Clinical Neurology and Neurosurgery 119 (2014) 6–16 13
Fig. 3. The pathophysiology of multiple sclerosis (MS) involves many inter-related and co-existing stages, depicted in a simpliﬁed step-wise manner in the top panel. Acute
relapses are a manifestation of new inﬂammatory activity in the CNS, driven by autoreactive T-cells that orchestrate an attack on myelin-producing oligodendrocytes (top left
panel).  Both the loss of oligodendrocytes and impaired remyelination (top middle panel) may  lead to the accumulation of relapse-related disability. Inﬂammatory lesions are
also  associated with axonal transection and loss, which may  occur early in the disease course and worsen over time (top right panel). Incomplete relapse recovery suggests that
neuronal  vulnerability after a relapse has important clinical implications. High-dose corticosteroids (CSs) are frequently employed to reduce acute CNS inﬂammation (bottom
left  panel). This short-term beneﬁt may  however come at the expense of optimal remyelination, as animal models have demonstrated CSs may potentiate oligodendrocyte
loss in certain brain areas (bottom middle panel) [99]. Further animal model data suggest CSs limit the development of neurons [90], and may  promote increased apoptosis
of  the neurons that form axons of the optic nerve (bottom right panel) [98]. This deleterious effect of CSs on neuron survival suggests that for some neurons, or in certain
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isease  process evolves, the unexpected effects of high-dose CSs on oligodendrocyt
esponses to the dexamethasone (DEX) suppression test and the
EX- adrenocorticotropic hormone (ACTH) releasing test [118].
edically healthy depressed patients have also been found to have
educed sensitivity to cutaneous CSs [119]. In MS  patients with
epression, impaired CS sensitivity has been identiﬁed using the
EX suppression test [120]. Depressed MS  patients have been found
o exhibit increased evening circulating concentrations of corti-
ol, which also suggests reduced CS sensitivity [121]. Depressed
atients with MS  have been reported to have elevated cortisol
oncentrations that are associated with reduced hippocampal vol-
me  [107]. The hippocampus is essential for normal regulation of
ypothalamic-pituitary adrenal (HPA) axis function [42], and the
oss of hippocampal control over the hypothalamus could result
n increased output of cortisol from the HPA axis. Finally, patients
ith depression have been shown to have reduced GR in circu-
ating lymphocytes, which could contribute to CS resistance in this
ubgroup of immune cells [52].
Observations of increased or inappropriate inﬂammatory activ-
ty in depressed patients combined with decreased CS sensitivity
n patients with both major depression and MS  may  give unique
nsight into the overlapping pathophysiologies of the disorders. It
as been proposed that altered immune function in major depres-
ion, including increased inﬂammation, may  take place subsequent
o CS resistance [57]. High-dose CS treatment, such as the IVMP
herapy used for MS  exacerbations, may  encourage a reducedclinically-relevant implications associated with the use of high-dose CSs. As the MS
 neurons may  potentiate disability, depression, and steroid resistance.
sensitivity  to CSs because of GR autoregulation. This, in turn, could
promote less GR-mediated inhibition of inﬂammatory signaling
pathways and an overall inﬂammatory excess, contributing to the
severity of major depression in these patients. The MS  patient with
depression is thus one example of a clinical phenotype where the
application of high-dose steroids should be done thoughtfully.
7.  Conclusion: implications for clinical practice and future
research
In  current clinical practice, it may  be difﬁcult to predict which
MS patients will respond favorably to CSs and those who might
respond sub-optimally, both in terms of therapeutic response and
tolerability proﬁle. In this opinion piece we  have covered some of
the diverse mechanisms that underscore this heterogeneous clin-
ical response to exogenous CSs in patients with MS.  We  propose
that there are speciﬁc cellular, systemic, and clinical characteristics
that might merit consideration when utilizing supraphysiological
doses of CSs in clinical practice. These characteristics must next
be tested in a translational setting to determine how they might
apply to patients. We  also hope to encourage the measurement of
long-term physiologic nuances in clinical studies of high-dose CSs,
rather than just short-term measures of inﬂammation.
The variable impact of CSs at a cellular level, mediated by
genomic effects and mutable expression of different GR isoforms,
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ould be examined as a potential contributor to CS responsive-
ess and heterogeneity of response in relapsing MS  patients.
lthough some of the genomic and nongeomic effects of CSs might
e desirable, many of the effects of supraphysiological doses of
Ss (e.g., 1 g of IVMP as used to treat MS  relapses) are poorly
nderstood and these treatments often present with serious side
ffects. Aside from the well-described side effects of metabolic
yndrome, bone loss, HPA axis dysregulation, and extreme mood
hifts [89], high-dose CSs may  have additional effects that are
mportant in MS,  such as the nongenomic interference with neu-
orepair processes [98,99]. Unfortunately, the majority of research
n genomic and nongenomic effects of CSs to date involves cell
ulture systems that may  poorly model a process that could vary
rom tissue to tissue and almost certainly is affected by cells act-
ng in vitro vs. in vivo. Exploring these cellular contributions to
S sensitivity across different cell types and organ systems may
ield ideas for side effect prediction and mediation. Biomarker
ssays for CS sensitivity, such as heat shock protein (HSP) 90
evels or GR expression, may  provide insight into individual
S responsiveness and allow for more rational patient selec-
ion for CS treatment and re-treatment over the course of a
atient’s MS.
It  is clear that the clinical impact of exogenous high-dose
Ss is more complex than a simple dose-response relationship.
he precise timing, dosage, duration of therapy, cellular expo-
ure, and background CS basal milieu all contribute to the pro- or
nti-inﬂammatory properties of CSs (Fig. 3) [90,98,99]. Although
ctivation state of immune cells is likely to be central to under-
tanding how immune cells function in the context of MS  and how
Ss may  act in MS  patients, a strong need exists to expand our
nderstanding of how CSs may  either protect or harm neurons,
r encourage or inhibit remyelination, especially in the setting of
n MS  exacerbation. The notion that exogenous CSs can exert a
roinﬂammatory effect where anti-inﬂammatory effects are
xpected, and could be potentially neurotoxic where neuroprotec-
ion is the goal, runs contrary to the accepted dogma guiding the
herapeutic use of CSs in MS  relapse.
Given the high rates of comorbid depression in MS  and the com-
lex interplay between the disease state, mood regulation, chronic
nﬂammation and CS resistance, the use of exogenous CSs in MS
atients with depression merits special consideration. It is per-
aps in this population that the chameleon-like qualities of CSs
re most evident. Corticosteroid resistance in depressed patients
s well established, and may  manifest as increased inﬂammatory
ctivity. In this setting, supraphysiological CS dosing may  in turn
oth worsen MS  and undercut normal CNS function required for
ood regulation, potentiating depression. Future investigations
hould work to determine if MS  combined with major depres-
ion is associated with resistance to therapy with CSs and may
eﬂect a clinical phenotype to speciﬁcally consider when treating
S relapses.
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